Study design and participants
Neuroblastoma
NEUROBLASTOMA, NEUROBLASTOMA
This was a prospective, open-label, single-arm, multicenter, Phase 2 study (APN311-304) in which single-agent dinutuximab beta, administered by continuous, long-term infusion, was investigated in patients with relapsed/refractory HR-NB. Patients aged 1–21 years with neuroblastoma, according to the International Neuroblastoma Staging System (INSS) criteria [